Alexion Pharmaceuticals Seeing Heavy Call Activity
January 4, 2017: Seeing heavy call activity in Alexion Pharmaceuticals: 2,000 Aug $140 calls traded at $12.80. I wonder if the heavy call activity has anything to do with the takeover rumors that were circulating on December 20, 2016, about Alexion Pharmaceuticals?
December 22, 2016: Leerink defending Alexion Pharmaceuticals; Reiterates outperform rating and price target of $211. Leerink says that the failure of Soliris for the prevention of delayed graft function (DGF) after kidney transplantation does not materially impact firms long-term Soliris forecasts or growth rate, but does represent another example of Alexion ploughing Soliris profits into high risk trials for low value indications. DGF represented less than $50M of annual global sales for their long-term Soliris forecasts (previous probability of success was 35%), and the removal does not impact firms valuation.
December 20, 2016: Hearing takeover rumors circulating about biotechnology firm Alexion Pharmaceuticals. The rumor is that a big (but unnamed) drug company has approached Alexion Pharmaceuticals with a takeover offer. The rumor is that Roche could be still interested in Alexion. The rumors are likely coming from this story: http://www.streetinsider.com/Hot+M+and+A/Alexion+Pharmaceuticals+%28ALXN%29+Said+to+Receive+Takeover+Approach+-+Source/12360443.html
I put a lot of credibility on this takeover rumor because the CEO Hallal left the company on 12/12/16 for “personal reasons” and CFO Sinha also left the company to “pursue other opportunities.” Sometimes when high-ranking officers in a company start leaving all of a sudden, something big is going on.
Alexion Pharmaceuticals Stock Chart
The Finviz screener settings used to find Alexion Pharmaceuticals are: Sector Healthcare, Sales growth past 5 years Over 30%, EPS growth qtr over qtr 100% – 200%, Gross Margin High (>50%)
Alexion is a biopharmaceutical company focused on serving patients with severe and rare disorders through the innovation, development, and commercialization of life-transforming therapeutic products.
Trading The News: Alexion Pharmaceuticals In The News
Alexion Pharmaceuticals, Inc. (ALXN) Price Target Cut to $177.00 by Analysts at Royal Bank Of Canada - The Cerbat Gem
February 20, 2017 - Alexion Pharmaceuticals, Inc. logo Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) had its price objective decreased by Royal Bank Of Canada from $187.00 to $177.00 in a research report report published on Friday. Royal Bank Of Canada currently has an ...
Alexion Shelves Rare-Disease Drug SBC-103 (ALXN) | Investopedia - Investopedia
February 20, 2017 - Alexion has shelved its mucopolysaccharidosis drug SBC-103, which it acquired in 2015.
Buy, Sell or Hold? Analysts Approach: Alexion Pharmaceuticals, Inc. (ALXN), Las Vegas Sands Corp. (LVS)? - The USA Commerce
February 20, 2017 - Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) dropped -1.20% to $128.82. During the trading on 02/17/2017, Company's stock ranged from $125.20 to $130.23. The relative strength index or RSI highlights overbought (above 70) and oversold ...
Analysts Buzz at Active Mover- ZosanoPharma Corporation (NASDAQ:ZSAN), Alexion Pharmaceuticals, Inc. (NASDAQ ... - Seneca Globe
February 20, 2017 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) [Trend Analysis] shows fluctuation in active trade, shares Dropped -1.20% to $128.82. Looking over the ALXN ranking chart, the ALXN got 17 analysts recommendation as a Buy security in previous month pool ...
Alexion Pharmaceuticals, Inc. (ALXN) Rating Reiterated by BMO Capital Markets - Sports Perspectives
February 19, 2017 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)'s stock had its “outperform” rating reissued by analysts at BMO Capital Markets in a note issued to investors on Sunday. They currently have a $158.00 price objective on the biopharmaceutical company's stock, ...
Nexthera Capital Lp Buys Novartis AG, Celgene, Alexion Pharmaceuticals, Sells GlaxoSmithKline PLC, Pfizer, Seattle ... - GuruFocus.com
February 16, 2017 - Investment company Nexthera Capital Lp buys Novartis AG, Celgene, Alexion Pharmaceuticals, Shire PLC, AstraZeneca PLC, Horizon Pharma PLC, Kite Pharma, Alnylam Pharmaceuticals, Minerva Neurosciences, Neurocrine Biosciences, sells ...
Alexion Pharma (ALXN) Plans to Be 'Very Active' on Deal Opportunities - StreetInsider.com
February 16, 2017 - Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here. On its call, Alexion Pharma (NASDAQ: ALXN) said it will be very active in ...
Alexion Pharma's Bloated Blockbuster Deal Still Haunts - TheStreet.com
February 16, 2017 - When Alexion Pharmaceuticals (ALXN) paid $8.4 billion to acquire Synageva Biopharma in May 2015, then CEO Lenny Bell told investors the high price tag was justified because Kanuma, Synageva's lead rare disease drug, would become a billion-dollar ...
BRIEF-Alexion Pharmaceuticals posts Q4 adj. earnings $1.26/shr - Reuters
February 16, 2017 - Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news ...
Sphera Funds Management Ltd. Buys Merck, Celgene, Alexion Pharmaceuticals, Sells Allergan PLC, Eli Lilly and Co ... - GuruFocus.com
February 13, 2017 - Investment company Sphera Funds Management Ltd. buys Merck, Celgene, Alexion Pharmaceuticals, Teva Pharmaceutical Industries, Shire PLC, Biomarin Pharmaceutical, Sarepta Therapeutics, Vertex Pharmaceuticals, Schlumberger, Acceleron Pharma, ...